- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Job Postings
- Events
Page 314
Keros bosses IPO to raise $96m
Partners Healthcare and Medison Pharma-backed Keros Therapeutics floated at the top of its range and will look to advance its musculoskeletal disorder drug candidates.
Apr 9, 2020Tyto Care takes $50m
The remote diagnostics technology developer increased its total funding to $105m in a round co-led by new investor Qualcomm Ventures.
Apr 9, 2020CyberMDX secures $20m
Mutual insurer Sham has led a $20m round for healthcare cybersecurity software provider CyberMDX that expanded its total funding to $30m.
Apr 8, 2020Daily deal net: April 8, 2020
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Apr 8, 2020Genechem generates series C funding
The translational medicine-focused research services provider, which counts Renfu Pharmaceutical as an investor, has completed a Humanwell-backed round sized at about $56m.
Apr 8, 2020Kringle Pharma rings up new funding
Chishima Real Estate and Miraca helped add $6.8m to extend Kringle‘s latest round to $15.5m which will fund development of its rare disease treatments.
Apr 8, 2020Sunland Fund succeeds with corporate-backed vehicle
Lepu Medical and Shandong Buchang Pharma were among the limited partners that have backed the healthcare investor's latest fund.
Apr 7, 2020Servier orchestrates Symphogen acquisition
Novo and Takeda are set to exit antibody therapy developer Symphogen in an acquisition by one of its strategic partners, Servier.
Apr 7, 2020Click Diagnostics picks up $70m
Cedars-Sinai Medical Center contributed to a round for the stealth-stage diagnostics technology developer, which raised $101m less than a year ago.
Apr 7, 2020Ribo Life Science realises series C2 round
SAIC Motor fund Hengxu Investment and a Sinopharm-backed joint venture were among the investors in a $66.3m round for the RNA drug developer.
Apr 7, 2020About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


